Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Abbott is developing Neuronal Nicotinic Receptors, NNRs

Loading...

Sign in or sign up now!
4,546
Loading...
Alert icon
Sign in or sign up now!
Alert icon
Ratings have been disabled for this video.

Uploaded by on Oct 21, 2008

Selective NNR compounds may offer a novel targeted approach to enhancing cognitive function in Alzheimers disease, schizophrenia and attention deficit hyperactivity disorder or ADHD. These compounds may be better tolerated with less potential for side effects than other activating agents.

All Comments

Adding comments has been disabled for this video.
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more